vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $177.4M, roughly 1.0× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs 0.9%, a 0.7% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 5.0%). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs -0.2%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
FOLD vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $177.4M |
| Net Profit | $1.7M | $2.9M |
| Gross Margin | 85.7% | — |
| Operating Margin | 8.6% | 3.9% |
| Net Margin | 0.9% | 1.6% |
| Revenue YoY | 23.7% | 5.0% |
| Net Profit YoY | -88.5% | — |
| EPS (diluted) | $0.00 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $185.2M | $196.9M | ||
| Q3 25 | $169.1M | $179.5M | ||
| Q2 25 | $154.7M | $181.1M | ||
| Q1 25 | $125.2M | $168.9M | ||
| Q4 24 | $149.7M | $187.3M | ||
| Q3 24 | $141.5M | $168.6M | ||
| Q2 24 | $126.7M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $1.7M | — | ||
| Q3 25 | $17.3M | $5.4M | ||
| Q2 25 | $-24.4M | $-4.8M | ||
| Q1 25 | $-21.7M | $4.8M | ||
| Q4 24 | $14.7M | — | ||
| Q3 24 | $-6.7M | $-143.5M | ||
| Q2 24 | $-15.7M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 85.7% | 79.5% | ||
| Q3 25 | 88.5% | 80.9% | ||
| Q2 25 | 90.2% | 77.4% | ||
| Q1 25 | 90.7% | 79.7% | ||
| Q4 24 | 90.1% | 78.7% | ||
| Q3 24 | 90.6% | 76.9% | ||
| Q2 24 | 91.1% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 8.6% | 1.2% | ||
| Q3 25 | 20.3% | 3.5% | ||
| Q2 25 | -6.1% | 4.7% | ||
| Q1 25 | -6.3% | 1.2% | ||
| Q4 24 | 10.7% | 13.2% | ||
| Q3 24 | 15.3% | -82.8% | ||
| Q2 24 | 11.8% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 0.9% | — | ||
| Q3 25 | 10.2% | 3.0% | ||
| Q2 25 | -15.8% | -2.7% | ||
| Q1 25 | -17.3% | 2.8% | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | -4.8% | -85.1% | ||
| Q2 24 | -12.4% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.00 | $0.05 | ||
| Q3 25 | $0.06 | $0.12 | ||
| Q2 25 | $-0.08 | $-0.11 | ||
| Q1 25 | $-0.07 | $0.10 | ||
| Q4 24 | $0.05 | $0.38 | ||
| Q3 24 | $-0.02 | $-3.11 | ||
| Q2 24 | $-0.05 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $144.3M |
| Total DebtLower is stronger | $392.7M | — |
| Stockholders' EquityBook value | $274.2M | $653.9M |
| Total Assets | $949.9M | $1.2B |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $293.5M | $238.4M | ||
| Q3 25 | $263.8M | $246.3M | ||
| Q2 25 | $231.0M | $445.9M | ||
| Q1 25 | $250.6M | $493.6M | ||
| Q4 24 | $249.9M | $484.6M | ||
| Q3 24 | $249.8M | $453.8M | ||
| Q2 24 | $260.1M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $392.7M | $372.2M | ||
| Q3 25 | $392.0M | $376.7M | ||
| Q2 25 | $391.3M | $580.5M | ||
| Q1 25 | $390.7M | $583.4M | ||
| Q4 24 | $390.1M | $585.3M | ||
| Q3 24 | $389.5M | — | ||
| Q2 24 | $388.9M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $274.2M | $693.1M | ||
| Q3 25 | $230.4M | $727.2M | ||
| Q2 25 | $204.3M | $757.8M | ||
| Q1 25 | $193.6M | $798.5M | ||
| Q4 24 | $194.0M | $778.3M | ||
| Q3 24 | $178.8M | $749.6M | ||
| Q2 24 | $132.5M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $949.9M | $1.3B | ||
| Q3 25 | $868.8M | $1.3B | ||
| Q2 25 | $815.3M | $1.5B | ||
| Q1 25 | $789.8M | $1.6B | ||
| Q4 24 | $785.0M | $1.6B | ||
| Q3 24 | $786.6M | $1.5B | ||
| Q2 24 | $749.5M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 0.54× | ||
| Q3 25 | 1.70× | 0.52× | ||
| Q2 25 | 1.92× | 0.77× | ||
| Q1 25 | 2.02× | 0.73× | ||
| Q4 24 | 2.01× | 0.75× | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.93× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | — |
| Free Cash FlowOCF − Capex | $16.0M | — |
| FCF MarginFCF / Revenue | 8.6% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 9.62× | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $16.3M | $43.7M | ||
| Q3 25 | $35.7M | $60.8M | ||
| Q2 25 | $-26.5M | $12.0M | ||
| Q1 25 | $7.8M | $35.5M | ||
| Q4 24 | $-3.9M | $33.1M | ||
| Q3 24 | $-23.0M | $53.9M | ||
| Q2 24 | $22.7M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $16.0M | $43.5M | ||
| Q3 25 | $35.3M | $57.0M | ||
| Q2 25 | $-28.9M | $9.3M | ||
| Q1 25 | $7.5M | $26.9M | ||
| Q4 24 | $-4.2M | $31.0M | ||
| Q3 24 | $-23.3M | $49.8M | ||
| Q2 24 | $21.6M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 8.6% | 22.1% | ||
| Q3 25 | 20.9% | 31.7% | ||
| Q2 25 | -18.7% | 5.1% | ||
| Q1 25 | 6.0% | 15.9% | ||
| Q4 24 | -2.8% | 16.6% | ||
| Q3 24 | -16.5% | 29.6% | ||
| Q2 24 | 17.0% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 0.1% | ||
| Q3 25 | 0.2% | 2.2% | ||
| Q2 25 | 1.6% | 1.5% | ||
| Q1 25 | 0.2% | 5.1% | ||
| Q4 24 | 0.2% | 1.1% | ||
| Q3 24 | 0.3% | 2.4% | ||
| Q2 24 | 0.9% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 9.62× | — | ||
| Q3 25 | 2.06× | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | -0.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
